Forwarded from Doomsday Tradecraft
🧬 Biotechnology is changing how we fight disease—and opening new possibilities for human health.
Four advances from September 2026:
🔬 ONE MEDICINE, TWO GENE TARGETS
Arrowhead’s experimental ARO-DIMER-PA suppresses PCSK9 and APOC3 together. Early results reported mean maximum reductions of 54% in LDL cholesterol and 73% in triglycerides after one dose. Whether it prevents heart attacks or strokes remains unproven.
🛡️ REACTIVATING IMMUNITY AGAINST CANCER
In 87 patients with previously treated metastatic squamous lung cancer, gotistobart produced median survival of 18.5 months versus 10 months with chemotherapy. These encouraging results still need confirmation in the pivotal portion of the trial.
💪 TARGETING MUSCLE LOSS
The FDA approved Isembyld for spinal muscular atrophy in patients aged 2+ receiving SMN2-targeted treatment. It blocks activation of myostatin—a natural brake on muscle growth—and demonstrated improved motor function.
⏳ INVESTIGATING BIOLOGICAL AGING
An analysis of 42 lung-fibrosis trial participants found that rentosertib shifted blood-protein aging estimates toward younger profiles. This does not yet prove rejuvenation or longer life.
The progress is real. Understanding the evidence helps us see how far each discovery has actually reached.
Sources: Arrowhead • BioNTech/OncoC4 • FDA/Scholar Rock • Nature Biotechnology
#Biotechnology #MedicalBreakthroughs #RNAtherapeutics #CancerResearch #LongevityScience
Four advances from September 2026:
🔬 ONE MEDICINE, TWO GENE TARGETS
Arrowhead’s experimental ARO-DIMER-PA suppresses PCSK9 and APOC3 together. Early results reported mean maximum reductions of 54% in LDL cholesterol and 73% in triglycerides after one dose. Whether it prevents heart attacks or strokes remains unproven.
🛡️ REACTIVATING IMMUNITY AGAINST CANCER
In 87 patients with previously treated metastatic squamous lung cancer, gotistobart produced median survival of 18.5 months versus 10 months with chemotherapy. These encouraging results still need confirmation in the pivotal portion of the trial.
💪 TARGETING MUSCLE LOSS
The FDA approved Isembyld for spinal muscular atrophy in patients aged 2+ receiving SMN2-targeted treatment. It blocks activation of myostatin—a natural brake on muscle growth—and demonstrated improved motor function.
⏳ INVESTIGATING BIOLOGICAL AGING
An analysis of 42 lung-fibrosis trial participants found that rentosertib shifted blood-protein aging estimates toward younger profiles. This does not yet prove rejuvenation or longer life.
The progress is real. Understanding the evidence helps us see how far each discovery has actually reached.
Sources: Arrowhead • BioNTech/OncoC4 • FDA/Scholar Rock • Nature Biotechnology
#Biotechnology #MedicalBreakthroughs #RNAtherapeutics #CancerResearch #LongevityScience
🔥1